Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
18.45 +0.25 +1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/7/15
  • Rating change
    B. Riley Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/8/25
  • Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $37
    Market Newswire · 2026/11/13
  • Rating change
    BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/5/11
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36
    Market Newswire · 2026/7/23
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/5/26
  • A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $24 to $42
    Market Newswire · 2026/11/5
  • Rating change
    J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29
    Market Newswire · 2026/7/13
  • Rating change
    UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $25
    Market Newswire · 2026/6/16
  • Rating change
    A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $41
    Market Newswire · 2026/8/7
  • Rating change
    Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40
    Market Newswire · 2026/5/14
  • Rating change
    H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/7/13
  • Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q3 Revenue $17.8M, Vs. FactSet Est of $12.2M
    MT Newswires · 2026/11/4
  • Rating change
    Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/7/16
  • GUIDANCE: (DNLI) Denali Therapeutics Inc. Expects Q4 Revenue Range $30.0M - $32.0M
    MT Newswires · 2026/11/4
  • Rating change
    Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/7/13
  • Rating change
    A Quick Look at Today's Ratings for Denali Therapeutics(DNLI.US), With a Forecast Between $31 to $42
    Market Newswire · 2026/8/8
  • Rating change
    J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/8/11
  • Rating change
    Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/5/11
  • Wells Fargo Initiates Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $35
    Market Newswire · 2026/11/13
  • Rating change
    William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating
    Market Newswire · 2026/5/9
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Agilon Health (AGL), CG Oncology, Inc. (CGON) and Denali Therapeutics (DNLI)
    TipRanks · 2026/5/9
  • Rating change
    Baird Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/4/7
  • Rating change
    Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $23
    Market Newswire · 2026/5/8
  • Rating change
    TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
    Market Newswire · 2026/5/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Denali Therapeutics discussion 0 comments

Add a comment